Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands

PharmacoEconomics

Volumn 30, Issue 3, 2012, Pages 219-227

  Hoomans, Ties ^a   Severens, Johan L ^b   Van Der Roer, Nicole ^c   Delwel, Gepke O ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Dutch Healthcare Insurance Board   (Netherlands)

Author keywords

Cost effectiveness; Decision making; Pharmacoeconomics; Reimbursement

Indexed keywords

BORTEZOMIB; ERLOTINIB; IVABRADINE; PALIVIZUMAB; WART VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; HUMAN; METHODOLOGY; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REIMBURSEMENT; REVIEW;

COSTS AND COST ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GUIDELINES AS TOPIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; NETHERLANDS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS;

EID: 84857256074     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11539850-000000000-00000     Document Type: Review

References (39)

1. Dutch Health Care Insurance Board. Dutch assessment procedures for the reimbursement of outpatient medicines Diemen: CVZ, 2010 [online]. Available from URL: http:// www.cvz.nl/binaries/live/cvzinternet/hst-content/nl/doc umenten/rubriek+zorgpakket/cfh/assessment-outpatientmedicines. pdf [Accessed 2011 Aug 11]
2. Dutch Health Care Insurance Board. Evaluatie farmacoeconomie: procedure en inhoud. Stand van zaken na 10 dossiers. Diemen: CVZ, 2004
3. Dutch Health Care Insurance Board. Dutch guidelines for pharmacoeconomic research, report. Diemen: CVZ, 1999
4. Oostenbrink JB, Bouwmans CA, Koopmanschap MA, et al., on behalf of the Dutch Health Care Insurance Board. Manual for cost analysis: methods and standard cost prices for economic evaluations in health care, updated version [in Dutch]. Diemen: CVZ, 2004
5. Dutch Health Care Insurance Board. Guidelines for pharmacoeconomic research, updated version. Diemen: CVZ, 2006 [online]. Available from URL: http://cvz.nl/binaries/con tent/documents/cvzinternet/nl/documenten/ rubriek+zorgp akket/cfh/richtlijnen+farmaco-economisch+onderzoek+-+ engels.pdf [Accessed 2011 Aug 11]
6. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
7. DrummondMF, SculpherMJ. Common methodological flaws in economic evaluations. Med Care 2005; 43 Suppl. 7: 5-14
8. Hoomans T, van der Roer N, Severens JL, et al. Costeffectiveness of new drugs impacts reimbursement decision making but room for improvement [in Dutch]. Ned Tijdschr Geneeskd 2010; 154 (30): A958
9. Dutch Health Care Insurance Board. Imiquimod (Aldara-) for basal cell carcinoma. Pharmacoeconomic report 2005 [in Dutch; online]. Available from URL: http://cvz.nl/bina ries/content/documents/cvzinternet/nl/documenten/cfh-rap porten/2005/cfh0507+imiquimod+aldara.pdf [Accessed 2011 Aug 11]
10. Dutch Health Care Insurance Board. Palivizumab (Synagis). Pharmacoeconomic report 2006 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/ cvzinternet/nl/documenten/cfh- rapporten/2006/cfh0609+paliv izumab+synagis.pdf [Accessed 2011 Aug 11]
11. Dutch Health Care Insurance Board. Oseltamivir (Tamiflu). Pharmacoeconomic report 2005 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/ cvzinternet/nl/documenten/cfh- rapporten/2005/ cfh0511+oseltamivir+tamiflu.pdf [Accessed 2011 Aug 11]
12. Dutch Health Care Insurance Board. Erlotinib (Tarceva). Pharmacoeconomic report 2006 [inDutch; online].Available from URL: http://www.cvz.nl/binaries/ content/documents/ cvzinternet/nl/documenten/cfh-rapporten/2006/cfh0603+erlo tinib+tarceva.pdf [Accessed 2011 Aug 11]
13. Dutch Health Care Insurance Board. Fentanyl (oromucosal route) [Actiq]. Pharmacoeconomic report 2006 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/cvzinternet/nl/documenten/cfh- rappor ten/2006/cfh0604+fentanyl-oromucosaal+actiq.pdf [Accessed 2011 Aug 11]
14. Dutch Health Care Insurance Board. Inhaled insulin (Exubera). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/cvzinternet/nl/documenten/cfh- rappor ten/2007/cfh0702+insuline+exubera.pdf [Accessed 2011 Aug 11]
15. Dutch Health Care Insurance Board. Grass pollen allergen extract (Grazax). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/cvzinternet/nl/documenten/cfh- rapporten/ 2007/cfh0704+timotheegras+grazax.pdf [Accessed 2011 Aug 11]
16. Dutch Health Care Insurance Board. Ivabradine (Procoralan). Pharmacoeconomic report 2006 [in Dutch; online]. Available from URL: http://cvz.nl/binaries/con tent/documents/cvzinternet/nl/documenten/cfh- rapporten/ 2006/cfh0604+ivabradine+procoralan.pdf [Accessed 2011 Aug 11]
17. Dutch Health Care Insurance Board. Dorzolamide preservative- free (Trusopt CV) [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/ cvzinternet/nl/documenten/cfh-rapporten/2006/cfh0610+do rzolamide+trusopt.pdf [Accessed 2011 Aug 11]
18. Dutch Health Care Insurance Board. Rimonabant (Acomplia). Pharmacoeconomic report [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/ cfh-rapporten/2007/cfh0703+rimonabant+acomplia.pdf [Accessed 2011 Aug 11]
19. Dutch Health Care Insurance Board. Exenatide (Byetta). Pharmacoeconomic report 2006 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/cvzinternet/nl/documenten/cfh-rapporten/2007/ cfh0709+exenatide+byetta.pdf [Accessed 2011 Aug 11]
20. Dutch Health Care Insurance Board. Human papillomavirus vaccine (Gardasil). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz. nl/binaries/content/documents/cvzinternet/nl/documenten/cfh- rapporten/2007/cfh0705+humaan-papillomavirusvaccin+ gardasil.pdf [Accessed 2011 Aug 11]
21. Dutch Health Care Insurance Board. Sitagliptine (Januvia-). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/docu ments/cvzinternet/nl/documenten/cfh- rapporten/2007/cfh0706 +sitagliptine+januvia.pdf [Accessed 2011 Aug 11]
22. DutchHealth Care Insurance Board. Ivabradine (Procoralan), reassessment. Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/ cfh-rappor ten/2007/cfh0706+ivabradine+procoralan.pdf [Accessed 2011 Aug 11]
23. Dutch Health Care Insurance Board. Rotavirusvaccin (Rotarix-). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/cvzinternet/nl/documenten/cfh- rappor ten/2007/cfh0709+rotavirus-vaccin+rotarix.pdf [Accessed 2011 Aug 11]
24. Dutch Health Care Insurance Board. Dasatinib (Sprycel-). Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/docu ments/cvzinternet/nl/documenten/cfh-rapporten/2007/cfh0 703+dasatinib+sprycel.pdf [Accessed 2011 Aug 11]
25. Dutch Health Care Insurance Board. Bortezomib (Velcade-). Pharmacoeconomic report 2007 [inDutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/ cvzinternet/nl/documenten/cfh- rapporten/2007/cfh0709+bor tezomib+velcade.pdf [Accessed 2011 Aug 11]
26. Dutch Health Care Insurance Board. Miconazol 0.25% (Zimycan), reassessment. Pharmacoeconomic report 2007 [in Dutch; online]. Available from URL: http://www.cvz. nl/binaries/content/documents/cvzinternet/nl/documenten/ cfh-rapporten/2007/cfh0706+miconazol-025+zimycan.pdf [Accessed 2011 Aug 11]
27. Dutch Health Care Insurance Board. Varenicline (Champix). Pharmacoeconomic report 2008 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/documents/ cvzinternet/nl/documenten/cfh- rapporten/2007/cfh0710+vare nicline+champix.pdf [Accessed 2011 Aug 11]
28. Dutch Health Care Insurance Board. Dabigatran (Pradaxa). Pharmacoeconomic report 2008 [inDutch; online]. Available from URL: http://www.cvz.nl/binaries/ content/documents/ cvzinternet/nl/documenten/cfh-rapporten/2008/cfh0806+dab igatran+pradaxa.pdf [Accessed 2011 Aug 11]
29. Dutch Health Care Insurance Board. Topotecan (Hycamtin), oral. Pharmacoeconomic report 2008 [in Dutch; online]. Available from URL: http://www.cvz.nl/binaries/content/ documents/cvzinternet/nl/documenten/cfh- rapporten/2008/ cfh0808+topotecan+hycamtin.pdf [Accessed 2010 Mar 17]
30. Dutch Health Care Insurance Board. CVZ-newsmails (formerly CVZ newsletters pharmacy) [in Dutch, online]. Available from URL: http://www.cvz.nl/publicaties/ cvz+nieuwsmail [Accessed 2011 Aug 11]
31. Velden ME, van Severens JL, Novak A. Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels. Pharmacoeconomics 2005; 23 (11): 1075-82 (Pubitemid 41633400)
32. Delwel GO, Sprenger MJ. Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget [in Dutch]. Ned Tijdschr Geneeskd 2002; 146 (23): 1068-71 (Pubitemid 34664036)
33. Postma J, De Jong-van den Berg LTW, Brouwers JR. Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations [in Dutch]. Ned Tijdschr Geneeskd 2002; 146 (23): 1082-7 (Pubitemid 34664040)
34. Williams I, McIver S, Moore D, et al. The use of economic evaluations inNHS decision-making: a review and empirical investigation. Health Technol Assess 2008; 12 (7): 1-175
35. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008; 28 (5): 713-22
36. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302 (13): 1437-43
37. Sculpher MJ, Drummond MF. Analysis sans frontiè res: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24 (11): 1087-99 (Pubitemid 44683366)
38. Drummond MJ, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009; 12 (4): 409-18
39. Cleemput I, van Wilder P, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009; 12 (4): 441-9